UBS Upgrades AngioDynamics (ANGO) to “Outperform”

UBS upgraded shares of AngioDynamics (NASDAQ:ANGO) from a market perform rating to an outperform rating in a research report report published on Tuesday, The Fly reports.

Other equities research analysts have also recently issued research reports about the stock. Canaccord Genuity raised their target price on shares of AngioDynamics from $16.50 to $17.00 and gave the stock a hold rating in a research note on Monday, April 2nd. Zacks Investment Research cut shares of AngioDynamics from a buy rating to a hold rating in a research note on Friday, January 26th. BidaskClub cut shares of AngioDynamics from a hold rating to a sell rating in a research note on Saturday, January 6th. Craig Hallum cut shares of AngioDynamics from a buy rating to a hold rating in a research note on Friday, January 5th. Finally, TheStreet cut shares of AngioDynamics from a b- rating to a c rating in a research note on Tuesday, January 2nd. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $17.87.

How to Become a New Pot Stock Millionaire

NASDAQ ANGO opened at $18.88 on Tuesday. AngioDynamics has a 12 month low of $14.80 and a 12 month high of $19.25. The company has a market cap of $700.76, a price-to-earnings ratio of 25.86, a PEG ratio of 1.72 and a beta of 1.00. The company has a current ratio of 2.88, a quick ratio of 1.84 and a debt-to-equity ratio of 0.16.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, March 29th. The medical instruments supplier reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.05. AngioDynamics had a net margin of 0.97% and a return on equity of 5.11%. The company had revenue of $83.85 million for the quarter, compared to analysts’ expectations of $86.13 million. analysts expect that AngioDynamics will post 0.74 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in the company. Fenimore Asset Management Inc. raised its position in shares of AngioDynamics by 0.6% during the fourth quarter. Fenimore Asset Management Inc. now owns 594,490 shares of the medical instruments supplier’s stock valued at $9,886,000 after buying an additional 3,715 shares during the last quarter. First Trust Advisors LP raised its position in shares of AngioDynamics by 13.7% during the fourth quarter. First Trust Advisors LP now owns 32,866 shares of the medical instruments supplier’s stock valued at $547,000 after buying an additional 3,968 shares during the last quarter. Legal & General Group Plc raised its position in shares of AngioDynamics by 7.0% during the third quarter. Legal & General Group Plc now owns 65,557 shares of the medical instruments supplier’s stock valued at $1,119,000 after buying an additional 4,296 shares during the last quarter. Highbridge Capital Management LLC raised its position in shares of AngioDynamics by 21.4% during the third quarter. Highbridge Capital Management LLC now owns 25,304 shares of the medical instruments supplier’s stock valued at $432,000 after buying an additional 4,461 shares during the last quarter. Finally, Nordea Investment Management AB raised its position in shares of AngioDynamics by 5.8% during the third quarter. Nordea Investment Management AB now owns 126,040 shares of the medical instruments supplier’s stock valued at $2,154,000 after buying an additional 6,948 shares during the last quarter. Hedge funds and other institutional investors own 97.09% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/3337712/ubs-upgrades-angiodynamics-ango-to-outperform.html.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities.

The Fly

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Capital One Financial Weighs in on Cousins Properties’ Q3 2018 Earnings
Capital One Financial Weighs in on Cousins Properties’ Q3 2018 Earnings
Royal Gold  Forecasted to Post Q3 2018 Earnings of $0.42 Per Share
Royal Gold Forecasted to Post Q3 2018 Earnings of $0.42 Per Share
Campbell Soup  Forecasted to Post Q3 2018 Earnings of $0.60 Per Share
Campbell Soup Forecasted to Post Q3 2018 Earnings of $0.60 Per Share
Infineon Technologies  PT Set at €28.00 by Goldman Sachs
Infineon Technologies PT Set at €28.00 by Goldman Sachs
Hauck & Aufhaeuser Reiterates €16.50 Price Target for Hamburger Hafen und Logistik
Hauck & Aufhaeuser Reiterates €16.50 Price Target for Hamburger Hafen und Logistik
Drägerwerk  Earns “Neutral” Rating from Deutsche Bank
Drägerwerk Earns “Neutral” Rating from Deutsche Bank


Leave a Reply

© 2006-2018 Ticker Report. Google+.